{"id":37324,"date":"2025-07-15T15:04:46","date_gmt":"2025-07-15T07:04:46","guid":{"rendered":"https:\/\/flcube.com\/?p=37324"},"modified":"2025-07-15T15:04:47","modified_gmt":"2025-07-15T07:04:47","slug":"bayer-ags-kerendia-approved-by-fda-to-treat-adult-heart-failure-with-ejection-fraction-%e2%89%a540","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37324","title":{"rendered":"Bayer AG&#8217;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%"},"content":{"rendered":"\n<p>German pharmaceutical giant Bayer AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.<\/p>\n\n\n\n<p><strong>Kerendia&#8217;s Mechanism and Benefits<\/strong><br>Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) designed to reduce the risk of cardiovascular death, HF hospitalization, and urgent HF visits. Its innovative mechanism of action provides a new therapeutic approach for managing heart failure.<\/p>\n\n\n\n<p><strong>Clinical Trial Support<\/strong><br>The FDA&#8217;s approval is supported by positive results from the pivotal Phase III FINEARTS-HF trial. The trial demonstrated Kerendia&#8217;s significant reduction in cardiovascular mortality and total HF events, including both first and recurrent episodes.<\/p>\n\n\n\n<p><strong>Global Marketing Applications<\/strong><br>Bayer has also submitted marketing authorization applications for this indication to China&#8217;s National Medical Products Administration (NMPA), the European Medicines Agency (EMA), and Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37325,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,69,967,15],"class_list":["post-37324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-cvd","tag-etr-bayn","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer AG&#039;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37324\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer AG&#039;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37324\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T07:04:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T07:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer AG&#8217;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%\",\"datePublished\":\"2025-07-15T07:04:46+00:00\",\"dateModified\":\"2025-07-15T07:04:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1504.webp\",\"keywords\":[\"Bayer\",\"CVD\",\"ETR: BAYN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37324#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37324\",\"name\":\"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1504.webp\",\"datePublished\":\"2025-07-15T07:04:46+00:00\",\"dateModified\":\"2025-07-15T07:04:47+00:00\",\"description\":\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37324\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37324#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer AG&#8217;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540% - Insight, China&#039;s Pharmaceutical Industry","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37324","og_locale":"en_US","og_type":"article","og_title":"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%","og_description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.","og_url":"https:\/\/flcube.com\/?p=37324","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-15T07:04:46+00:00","article_modified_time":"2025-07-15T07:04:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37324#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37324"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer AG&#8217;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%","datePublished":"2025-07-15T07:04:46+00:00","dateModified":"2025-07-15T07:04:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37324"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37324#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","keywords":["Bayer","CVD","ETR: BAYN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37324#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37324","url":"https:\/\/flcube.com\/?p=37324","name":"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37324#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37324#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","datePublished":"2025-07-15T07:04:46+00:00","dateModified":"2025-07-15T07:04:47+00:00","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Kerendia (finerenone) to treat adult heart failure (HF) patients with ejection fraction \u226540%. This approval marks a significant advancement in the treatment options for this specific patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37324#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37324"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37324#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","width":1080,"height":608,"caption":"Bayer AG's Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37324#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer AG&#8217;s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction \u226540%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37324"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37324\/revisions"}],"predecessor-version":[{"id":37326,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37324\/revisions\/37326"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37325"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}